CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Growth Hormone Releasing Hormone (Tesamorelin)drug
Likely dose
Growth Hormone Releasing Hormone (Tesamorelin) 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00850564
NCT00850564N/ACompleted
CompareCT.gov

Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Massachusetts General Hospital·interventional·Posted Feb 25, 2009·Updated Apr 19, 2011

In Brief

A clinical study evaluating Growth Hormone Releasing Hormone (Tesamorelin) for Healthy Volunteers. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2009
Enrollment StartFeb 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.4 years ago

Interventions

Growth Hormone Releasing Hormone (Tesamorelin)drug

Tesamorelin 2mg subcutaneous daily x 2 weeks